Leukemia Therapeutics Market to 2018 - Strong Late-stage Pipeline to Sustain Branded Drugs% Major Market Share

• Publication date: November 2012
• Report size: 145 pages

Leukemia Therapeutics Market to 2018 - Strong Late-stage Pipeline to Sustain Branded Drugs' Major Market Share Summary GBI Research, the leading business intelligence provider, has released its latest research “Leukemia Therapeutics Market to 2018 - Strong Late-stage Pipeline to Sustain Branded Drugs' Major Market Share” which provides insights into leukemia therapeutics market until 2018 for four major i...

Leukemia Therapeutics Market to 2018 - Strong Late-stage Pipeline to Sustain Branded Drugs' Major Market Share



Summary



GBI Research, the leading business intelligence provider, has released its latest research “Leukemia Therapeutics Market to 2018 - Strong Late-stage Pipeline to Sustain Branded Drugs' Major Market Share” which provides insights into leukemia therapeutics market until 2018 for four major indications. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

The report provides an in-depth analysis of the major leukemia indications including acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myelocytic leukemia (AML) and chronic myelocytic leukemia (CML). The report examines the global leukemia diseases treatment usage patterns. In addition, the geographical distribution of leukemia therapeutics and markets across the US, the top five countries of Europe and in Japan are provided in the report. The report also includes insights into the leukemia therapeutics R&D product pipeline and explores the competitive landscape including major players in the leukemia therapeutics market. Finally, the report also includes analysis on Mergers and Acquisitions (M&As) and licensing agreements that took place in leukemia therapeutics market.

In 2011, the leukemia therapeutics market for four major leukemia indications was estimated at $4.0 billion, indicating a compound annual growth rate (CAGR) of 21.0% since 2004. GBI Research forecasts the market to grow at a CAGR of 9.5% between 2011 and 2018 to reach to $7.6 billion by 2018. The four indications covered are treatment of acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myelogenous leukemia (AML) and chronic myelogenous leukemia (CML). The historic growth in major markets such as the US, the top five countries of Europe and Japan were driven mainly by the increasing prevalence and prescription population as well as launch of newer brands such as Sprycel, Tasigna, Clolar and Arranon with no major patent expirations. The US was the leading market with an estimated sales value of $1.8 billion in 2011 and an approximate share of 44.3%. The US market is expected to grow at a CAGR of 10.0% between 2011 and 2018 to record sales value of $3.5 billion in 2018. The top five countries of Europe together contributed to sales worth $1.5 billion in 2011, accounting for an approximate share of 37.9%. The top five countries of Europe are expected to record sales worth $3.1 billion by the year 2018, at a CAGR of 10.3%. Japan, in 2011, contributed $720m to the global market increasing at a CAGR of 20.8% from 2004. It accounts for an approximate share of 17.8%. Growing at a CAGR of 6.1% between 2011 and 2018, the market is expected to record sales worth $1.1 billion by 2018.



Scope


- Data and analysis on the leukemia therapeutics market in the leading geographies of the world – the US, Japan, the UK, Germany, France, Italy and Spain
- Annualized market data for the leukemia therapeutics market from 2004 to 2011, with forecasts to 2018
- Market data on the geographical landscape and therapeutic landscape, including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population, treatment seeking population, diagnosis population and prescription population
- Key drivers and restraints that have had a significant impact on the market
- The competitive landscape of the global leukemia therapeutics market including top companies benchmarking. The key companies studied in this report are Novartis AG, GlaxoSmithKline plc (GSK), Genzyme Corporation, Bristol-Myers Squibb Company (BMS) and Eisai Co., Ltd.
- Key M&A activities and licensing agreements that took place in 2009 and 2011 in the leukemia therapeutics market.



Reasons to buy


- Align your product portfolio to the markets with high growth potential.
- Build effective strategies to launch their pipeline products by identifying potential geographies.
- Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps.
- Develop key strategic initiatives by studying the key strategies of top competitors.
- Device a more tailored country strategy through the understanding of key drivers and barriers and market potential of each indication.
- Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules which are safer and more efficacious.

Global Pathology Industry

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 8
1.2 List of Figures 10
2 Leukemia Market to 2018 - Introduction 12
3 Leukemia Market to 2018 - Market Overview 13
3.1 Introduction 13
3.1.1 Revenue 13
3.1.2 Annual Cost of Treatment 15
3.1.3 Treatment Usage Pattern 16
3.2 Drivers and Barriers 18
3.2.1 Drivers for the Leukemia Therapeutics Market 18
3.2.2 Barriers for the Leukemia Therapeutics Market 19
4 Leukemia Market to 2018 - Geographical Landscape 20
4.1 Revenue Analysis by Geography 20
4.2 The US 22
4.2.1 Revenue 22
4.2.2 Annual Cost of Therapy 23
4.2.3 Treatment Usage Pattern 24
4.3 Top Five Countries of Europe 26
4.3.1 Revenue 26
4.3.2 Annual Cost of Therapy 28
4.3.3 Treatment Usage Pattern 30
4.4 Japan 32
4.4.1 Revenue 32
4.4.2 Annual Cost of Therapy 33
4.4.3 Treatment Usage Pattern 34
5 Leukemia Market to 2018 - Therapeutic Landscape 36
5.1 Acute Lymphocytic Leukemia (ALL) Therapeutics Market 36
5.1.1 Introduction 36
5.1.2 Classification 37
5.1.3 Epidemiology 38
5.1.4 Signs and Symptoms 39
5.1.5 Treatment and Management Pattern 40
5.1.6 Revenue 41
5.1.7 Annual Cost of Treatment 46
5.1.8 Treatment Usage Pattern 47
5.1.9 Major Marketed Products 49
5.1.10 Drivers and Barriers for the ALL Therapeutics Market 51
5.2 Chronic Lymphocytic Leukemia Therapeutics Market 52
5.2.1 Introduction 52
5.2.2 Epidemiology 53
5.2.3 Symptoms 53
5.2.4 Diagnosis 53
5.2.5 Treatment 55
5.2.6 Revenue 56
5.2.7 Annual Cost of Treatment 60
5.2.8 Treatment Usage Pattern 61
5.2.9 Major Marketed Products 63
5.2.10 Drivers and Barriers for the CLL Therapeutics Market 65
5.3 Acute Myelogenous Leukemia Therapeutics Market 66
5.3.1 Introduction 66
5.3.2 Epidemiology 68
5.3.3 Symptoms 68
5.3.4 Staging of AML 69
5.3.5 Diagnosis 69
5.3.6 Treatment by Stage 71
5.3.7 Revenue 72
5.3.8 Annual Cost of Treatment 76
5.3.9 Treatment Usage Pattern 77
5.3.10 Major Marketed Products 79
5.3.11 Drivers and Barriers for the AML Therapeutics Market 80
5.4 Chronic Myelogenous Leukemia Therapeutics Market 82
5.4.1 Introduction 82
5.4.2 Epidemiology 82
5.4.3 Staging 83
5.4.4 Symptoms 83
5.4.5 Diagnosis 84
5.4.6 Treatment of CML 84
5.4.7 Revenue 85
5.4.8 Annual Cost of Treatment 90
5.4.9 Treatment Usage Pattern 91
5.4.10 Major Marketed Products 93
5.4.11 Drivers and Barriers for the CML Therapeutics Market 96
6 Leukemia Market to 2018 - Pipeline Analysis 98
6.1 Introduction 98
6.2 Pipeline Assessment by Indication 100
6.2.1 Acute Lymphocytic Leukemia 100
6.2.2 Chronic Lymphocytic Leukemia 101
6.2.3 Acute Myelogenous Leukemia 102
6.2.4 Chronic Myelogenous Leukemia 103
6.3 Profiles of Promising Molecules for Leukemia 104
6.3.1 DepoCyte (liposomal cytarabine) 104
6.3.2 GRASPA (L-asparaginase) 104
6.3.3 Marqibo (vincristine sulfate liposomes injection) 105
6.3.4 GA101 (Obinutuzumab, RO5072759, RG7159) 106
6.3.5 Revlimid (lenalidomide) 107
6.3.6 Clolar (clofarabine) 108
6.3.7 Dacogen (decitabine) 109
6.3.8 Midostaurin (PKC 412) 110
6.3.9 Quizartinib (AC220) 111
6.3.10 Sapacitabine 111
6.3.11 Tosedostat (CHR-2797) 113
6.3.12 Vidaza (azacitadine) 114
6.3.13 Vosaroxin 115
6.3.14 Omapro (omacetaxine mepesuccinate) 116
6.3.15 Bosutinib (SKI-606) 117
7 Leukemia Market to 2018 - Competitive Landscape 118
7.1 Novartis AG 118
7.1.1 Company Overview 118
7.1.2 SWOT Analysis 118
7.2 GlaxoSmithKline plc (GSK) 119
7.2.1 Company Overview 119
7.2.2 SWOT Analysis 119
7.3 Genzyme Corporation 120
7.3.1 Company Overview 120
7.3.2 SWOT Analysis 120
7.4 Bristol-Myers Squibb Company (BMS) 121
7.4.1 Company Overview 121
7.4.2 SWOT Analysis 121
7.5 Eisai Co., Ltd. 122
7.5.1 Company Overview 122
7.5.2 SWOT Analysis 122
8 Leukemia Market to 2018 - Strategic Consolidations 123
8.1 Analysis by Deal Type 123
8.2 Analysis by Indication 124
8.3 Mergers & Acquisitions 125
8.3.1 Segmentation by Year 125
8.3.2 Segmentation by Geography 126
8.3.3 Segmentation by Value 127
8.3.4 Major Mergers and Acquisitions 127
8.4 Licensing Agreements 129
8.4.1 Segmentation by Year 129
8.4.2 Segmentation by Geography 130
8.4.3 Segmentation by Value 131
8.4.4 Major Licensing Agreements 132
8.5 Co-development Deals 134
8.5.1 Segmentation by Year 134
8.5.2 Segmentation by Geography 135
8.5.3 Segmentation by Value 135
8.5.4 Major Co-Development Deals 136
9 Leukemia Market to 2018 - Appendix 137
9.1 Market Definitions 137
9.2 Abbreviations 137
9.3 Bibliography 139
9.4 Research Methodology 140
9.4.1 Coverage 140
9.4.2 Secondary Research 141
9.4.3 Primary Research 141
9.4.4 Therapeutic Landscape 142
9.4.5 Market Size by Geography 144
9.4.6 Geographical Landscape 145
9.4.7 Pipeline Analysis 145
9.4.8 Competitive Landscape 145
9.4.9 Expert Panel Validation 145
9.5 Contact Us 145
9.6 Disclaimer 145

1.1 List of Tables

Table 1: Leukemia Market to 2018, Global, Revenue ($bn), 2004-2011 13
Table 2: Leukemia Market to 2018, Global, Revenue Forecasts ($bn), 2011-2018 13
Table 3: Leukemia Market to 2018, Global, Annual Cost of Treatment ($), 2004-2011 15
Table 4: Leukemia Market to 2018, Global, Annual Cost of Treatment Forecasts ($), 2011-2018 15
Table 5: Leukemia Market to 2018, Global, Treatment Usage Pattern, Population (thousand), 2004-2011 16
Table 6: Leukemia Market to 2018, Global, Treatment Usage Pattern, Population (thousand) Forecasts, 2011-2018 17
Table 7: Leukemia Market to 2018, Global, Revenue, By Country ($m), 2004-2011 20
Table 8: Leukemia Market to 2018, Global, Revenue Forecasts, By Country ($m), 2011-2018 21
Table 9: Leukemia Market to 2018, The US, Revenue ($m), 2004-2011 22
Table 10: Leukemia Market to 2018, The US, Revenue Forecasts ($m), 2011-2018 22
Table 11: Leukemia Market to 2018, The US, Annual Cost of Treatment ($), 2004-2011 23
Table 12: Leukemia Market to 2018, The US, Annual Cost of Treatment Forecasts ($), 2011-2018 23
Table 13: Leukemia Market to 2018, The US, Treatment Usage Pattern, Population (thousand), 2004-2011 24
Table 14: Leukemia Market to 2018, The US, Treatment Usage Pattern, Population (thousand) Forecasts, 2011-2018 25
Table 15: Leukemia Market to 2018, Top Five Countries of Europe, Revenue ($m), 2004-2011 26
Table 16: Leukemia Market to 2018, Top Five Countries of Europe, Revenue Forecasts ($m), 2011-2018 26
Table 17: Leukemia Market to 2018, Top Five Countries of Europe, Revenue, By Country ($m), 2004-2011 27
Table 18: Leukemia Market to 2018, Top Five Countries of Europe, Revenue Forecasts, By Country ($m), 2011-2018 28
Table 19: Leukemia Market to 2018, Top Five Countries of Europe, Annual Cost of Treatment ($), 2004-2011 29
Table 20: Leukemia Market to 2018, Top Five Countries of Europe, Annual Cost of Treatment ($) Forecasts, 2011-2018 29
Table 21: Leukemia Market to 2018, Top Five Countries of Europe, Treatment Usage Pattern, Population (thousand), 2004-2011 30
Table 22: Leukemia Market to 2018, Top Five Countries of Europe, Treatment Usage Pattern, Population (thousand), 2011-2018 31
Table 23: Leukemia Market to 2018, Japan, Revenue ($m), 2004-2011 32
Table 24: Leukemia Market to 2018, Japan, Revenue Forecasts ($m), 2011-2018 32
Table 25: Leukemia Market to 2018, Japan, Annual Cost of Treatment ($), 2004-2011 33
Table 26: Leukemia Market to 2018, Japan, Annual Cost of Treatment ($), 2011-2018 33
Table 27: Leukemia Market to 2018, Japan, Treatment Usage Pattern, Population, 2004-2011 34
Table 28: Leukemia Market to 2018, Japan, Treatment Usage Pattern, Population Forecasts, 2011-2018 35
Table 29: Leukemia Market to 2018, Acute Lymphocytic Leukemia, FAB Classification, 2012 37
Table 30: Leukemia Market to 2018, Acute Lymphocytic Leukemia, Incidence Rate by Age, 2007 38
Table 31: Leukemia Market to 2018, Acute Lymphocytic Leukemia, Incidence Rates by Race, 2007 39
Table 32: Leukemia Market to 2018, Acute Lymphocytic Leukemia, Treatment: Targeted Chemotherapy 41
Table 33: Leukemia Market to 2018, Acute Lymphocytic Leukemia, Global, Revenue ($m), 2004-2011 42
Table 34: Leukemia Market to 2018, Acute Lymphocytic Leukemia, Global, Revenue Forecasts ($m), 2011-2018 42
Table 35: Leukemia Market to 2018, Acute Lymphocytic Leukemia, Global, Revenue By Country ($m), 2004-2011 43
Table 36: Leukemia Market to 2018, Acute Lymphocytic Leukemia, Global, Revenue Forecast By Country ($m), 2011-2018 44
Table 37: Leukemia Market to 2018, Acute Lymphocytic Leukemia, Global, Annual Cost of Treatment ($), 2004-2011 46
Table 38: Leukemia Market to 2018, Acute Lymphocytic Leukemia, Global, Annual Cost of Treatment Forecasts ($), 2011-2018 46
Table 39: Leukemia Market to 2018, Acute Lymphocytic Leukemia, Global, Treatment Usage Pattern, 2004-2011 47
Table 40: Leukemia Market to 2018, Acute Lymphocytic Leukemia, Global, Treatment Usage Pattern, 2011-2018 48
Table 41: Leukemia Market to 2018, Chronic Lymphocytic Leukemia, Rai Staging System, The US, 2012 54
Table 42: Leukemia Market to 2018, Chronic Lymphocytic Leukemia, Binet Staging System, Europe, 2012 55
Table 43: Leukemia Market to 2018, Chronic Lymphocytic Leukemia, Global, Revenue ($m), 2004-2011 56
Table 44: Leukemia Market to 2018, Chronic Lymphocytic Leukemia, Global, Revenue Forecasts ($m), 2011-2018 56
Table 45: Leukemia Market to 2018, Chronic Lymphocytic Leukemia, Global, Revenue by Country ($m), 2004-2011 57
Table 46: Leukemia Market to 2018, Chronic Lymphocytic Leukemia, Global, Revenue Forecasts by Country ($m), 2011-2018 58
Table 47: Leukemia Market to 2018, Chronic Lymphocytic Leukemia, Global, Annual Cost of Treatment ($), 2004-2011 60
Table 48: Leukemia Market to 2018, Chronic Lymphocytic Leukemia, Global, Annual Cost of Treatment ($), 2011-2018 61
Table 49: Leukemia Market to 2018, Chronic Lymphocytic Leukemia, Global, Treatment Usage Pattern, Population (thousand), 2004-2011 62
Table 50: Leukemia Market to 2018, Chronic Lymphocytic Leukemia, Global, Treatment Usage Pattern, Population (thousand), 2011-2018 62
Table 51: Leukemia Market to 2018, WHO Classification of AML, 2012 67
Table 52: Leukemia Market to 2018, The French-American-British (FAB) Classification of AML, 2012 68
Table 53: Leukemia Market to 2018, Acute Myelogenous Leukemia, Global, Revenue ($m), 2004-2011 72
Table 54: Leukemia Market to 2018, Acute Myelogenous Leukemia, Global, Revenue Forecasts ($m), 2011-2018 72
Table 55: Leukemia Market to 2018, Acute Myelogenous Leukemia, Global, Revenue by Country ($m), 2004-2011 74
Table 56: Leukemia Market to 2018, Acute Myelogenous Leukemia, Global, Revenue by Country ($m), 2011-2018 74
Table 57: Leukemia Market to 2018, Acute Myelogenous Leukemia, Global, Annual Cost of Treatment ($), 2004-2011 76
Table 58: Leukemia Market to 2018, Acute Myelogenous Leukemia, Global, Annual Cost of Treatment ($), 2011-2018 76
Table 59: Leukemia Market to 2018, Acute Myelogenous Leukemia, Global, Treatment Usage Pattern, Population (thousand), 2004-2011 77
Table 60: Leukemia Market to 2018, Acute Myelogenous Leukemia, Global, Treatment Usage Pattern, Population (thousand), 2011-2018 78
Table 61: Leukemia Market to 2018, Chronic Myelogenous Leukemia, Global, Diagnosis Percentage by Age Group, 2004-2008 82
Table 62: Leukemia Market to 2018, Chronic Myelogenous Leukemia, Global, Revenue ($bn), 2004-2011 86
Table 63: Leukemia Market to 2018, Chronic Myelogenous Leukemia, Global, Revenue Forecasts, ($bn), 2011-2018 86
Table 64: Leukemia Market to 2018, Chronic Myelogenous Leukemia, Global, Revenue by Country ($m), 2004-2011 88
Table 65: Leukemia Market to 2018, Chronic Myelogenous Leukemia, Global, Revenue by Country ($m), 2011-2018 88
Table 66: Leukemia Market to 2018, Chronic Myelogenous Leukemia, Global, Annual Cost of Treatment ($), 2004-2011 90
Table 67: Leukemia Market to 2018, Chronic Myelogenous Leukemia, Global, Annual Cost of Treatment ($), 2011-2018 90
Table 68: Leukemia Market to 2018, Chronic Myelogenous Leukemia, Global, Treatment Usage Pattern, Population (thousand), 2004-2011 91
Table 69: Leukemia Market to 2018, Chronic Myelogenous Leukemia, Global, Treatment Usage Pattern, Population (thousand), 2011-2018 92
Table 70: Leukemia Market to 2018, Global, Mergers and Acquisitions, 2009-2011 127
Table 71: Leukemia Market to 2018, Global, Licensing Agreements, 2009-2011 132
Table 72: Leukemia Market to 2018, Global, Co-Development Deals, 2009-2011 136

1.2 List of Figures

Figure 1: Leukemia Market to 2018, Global, Revenue Forecasts ($bn), 2004-2018 13
Figure 2: Leukemia Market to 2018, Global, Branded vs. Generics (%), 2011-2018 14
Figure 3: Leukemia Market to 2018, Global, Annual Cost of Treatment ($), 2004-2018 15
Figure 4: Leukemia Market to 2018, Global, Treatment Usage Pattern, Population (thousand), 2004-2018 16
Figure 5: Leukemia Market to 2018, Global, Drivers and Barriers 18
Figure 6: Leukemia Market to 2018, Global, Revenue Forecasts, By Country ($m), 2004-2018 20
Figure 7: Leukemia Market to 2018, The US, Revenue Forecasts ($m), 2004-2018 22
Figure 8: Leukemia Market to 2018, The US, Annual Cost of Treatment ($), 2004-2018 23
Figure 9: Leukemia Market to 2018, The US, Treatment Usage Pattern, Population (thousand), 2004-2018 24
Figure 10: Leukemia Market to 2018, Top Five Countries of Europe, Revenue Forecasts ($m), 2004-2018 26
Figure 11: Leukemia Market to 2018, Top Five Countries of Europe, Revenue Forecasts, By Country ($m), 2004-2018 27
Figure 12: Leukemia Market to 2018, Top Five Countries of Europe, Annual Cost of Treatment ($), 2004-2018 28
Figure 13: Leukemia Market to 2018, Top Five Countries of Europe, Treatment Usage Pattern, Population (thousand), 2004-2018 30
Figure 14: Leukemia Market to 2018, Japan, Revenue Forecasts ($m), 2004-2018 32
Figure 15: Leukemia Market to 2018, Japan, Annual Cost of Treatment ($), 2004-2018 33
Figure 16: Leukemia Market to 2018, Japan, Treatment Usage Pattern, Population, 2004-2018 34
Figure 17: Leukemia Market to 2018, Acute Lymphocytic Leukemia, Global, Revenue Forecasts ($m), 2004-2018 41
Figure 18: Leukemia Market to 2018, Acute Lymphocytic Leukemia, Global, Revenue By Country ($m), 2004-2018 43
Figure 19: Leukemia Market to 2018, Acute Lymphocytic Leukemia, Global, Branded vs. Generics (%), 2011-2018 45
Figure 20: Leukemia Market to 2018, Acute Lymphocytic Leukemia, Global, Annual Cost of Treatment ($), 2004-2018 46
Figure 21: Leukemia Market to 2018, Acute Lymphocytic Leukemia, Global, Treatment Usage Pattern, 2004-2018 47
Figure 22: Leukemia Market to 2018, Acute Lymphocytic Leukemia, Global, Drivers and Barriers 51
Figure 23: Leukemia Market to 2018, Chronic Lymphocytic Leukemia, Global, Revenue Forecasts ($m), 2004-2018 56
Figure 24: Leukemia Market to 2018, Chronic Lymphocytic Leukemia, Global, Revenue by Country ($m), 2004-2018 57
Figure 25: Leukemia Market to 2018, Chronic Lymphocytic Leukemia, Global, Branded vs. Generics (%), 2011-2018 59
Figure 26: Leukemia Market to 2018, Chronic Lymphocytic Leukemia, Global, Annual Cost of Treatment ($), 2004-2018 60
Figure 27: Leukemia Market to 2018, Chronic Lymphocytic Leukemia, Global, Treatment Usage Pattern, Population (thousand), 2004-2018 61
Figure 28: Leukemia Market to 2018, Chronic Lymphocytic Leukemia, Global, Drivers and Barriers 65
Figure 29: Leukemia Market to 2018, Acute Myelogenous Leukemia, Global, Revenue Forecasts ($m), 2004-2018 72
Figure 30: Leukemia Market to 2018, Acute Myelogenous Leukemia, Global, Revenue by Country ($m), 2004-2018 73
Figure 31: Leukemia Market to 2018, Acute Myelogenous Leukemia, Global, Branded vs. Generics (%), 2011-2018 75
Figure 32: Leukemia Market to 2018, Acute Myelogenous Leukemia, Global, Annual Cost of Treatment ($), 2004-2018 76
Figure 33: Leukemia Market to 2018, Acute Myelogenous Leukemia, Global, Treatment Usage Pattern, Population (thousand), 2004-2018 77
Figure 34: Leukemia Market to 2018, Acute Myelogenous Leukemia, Global, Drivers and Barriers 80
Figure 35: Leukemia Market to 2018, Chronic Myelogenous Leukemia, Global, Different Stages of CML 83
Figure 36: Leukemia Market to 2018, Chronic Myelogenous Leukemia, Global, Revenue ($bn), 2004-2018 85
Figure 37: Leukemia Market to 2018, Chronic Myelogenous Leukemia, Global, Revenue by Country ($m), 2004-2018 87
Figure 38: Leukemia Market to 2018, Chronic Myelogenous Leukemia, Global, Branded vs. Generics (%), 2004-2018 89
Figure 39: Leukemia Market to 2018, Chronic Myelogenous Leukemia, Global, Annual Cost of Treatment ($), 2004-2018 90
Figure 40: Leukemia Market to 2018, Chronic Myelogenous Leukemia, Global, Treatment Usage Pattern, Population (thousand), 2004-2018 91
Figure 41: Leukemia Market to 2018, Chronic Myelogenous Leukemia, Global, Drivers and Barriers 96
Figure 42: Leukemia Market to 2018, Global, R&D Pipeline by Indications, 2011 98
Figure 43: Leukemia Market to 2018, Global, R&D Pipeline by Phase, 2011 99
Figure 44: Leukemia Market to 2018, Acute Lymphocytic Leukemia, Global, R&D Pipeline, 2011 100
Figure 45: Leukemia Market to 2018, Chronic Lymphocytic Leukemia, Global, R&D Pipeline, 2011 101
Figure 46: Leukemia Market to 2018, Acute Myelogenous Leukemia, Global, R&D Pipeline, 2011 102
Figure 47: Leukemia Market to 2018, Chronic Myelogenous Leukemia, Global, R&D Pipeline, 2011 103
Figure 48: Leukemia Market to 2018, Novartis AG, SWOT, 2011 118
Figure 49: Leukemia Market to 2018, GlaxoSmithKline Plc, SWOT, 2011 119
Figure 50: Leukemia Market to 2018, Genzyme Corporation, SWOT, 2011 120
Figure 51: Leukemia Market to 2018, Bristol-Myers Squibb Company, SWOT, 2011 121
Figure 52: Leukemia Market to 2018, Eisai Co., Ltd., SWOT, 2011 122
Figure 53: Leukemia Market to 2018, Global, All Deals, by Type, 2009-2011 123
Figure 54: Leukemia Market to 2018, Global, All Deals, By Indication, 2009-2011 124
Figure 55: Leukemia Market to 2018, Global, Mergers and Acquisitions, By Year, 2009-2011 125
Figure 56: Leukemia Market to 2018, Global, Mergers and Acquisitions, By Geography, 2009-2011 126
Figure 57: Leukemia Market to 2018, Global, Mergers and Acquisitions, By Value, 2009-2011 127
Figure 58: Leukemia Market to 2018, Global, Licensing Agreements, By Year, 2009-2011 129
Figure 59: Leukemia Market to 2018, Global, Licensing Agreements, By Geography, 2009-2011 130
Figure 60: Leukemia Market to 2018, Global, Licensing Agreements, By Value, 2009-2011 131
Figure 61: Leukemia Market to 2018, Global, Co-development Deals, By Year, 2009-2011 134
Figure 62: Leukemia Market to 2018, Global, Co-Development Deals, By Geography, 2009-2011 135
Figure 63: Leukemia Market to 2018, Global, Co-Development Deals, By Value, 2009-2011 135
Figure 64: GBI Research Market Forecasting Model 144

Companies Mentioned
Novartis AG
GlaxoSmithKline plc (GSK)
Genzyme Corporation
Bristol-Myers Squibb Company (BMS)
Eisai Co., Ltd.

Cancer in World

Iraq Prostate Cancer, 45-59 Yrs, Male, Dalys

• $ 250
• Industry data
• May 2013

Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research

• Industries : Pathology
• Countries : Iraq, World

Cook Islands Prostate Cancer, 70+ Yrs, Male, Dalys

• $ 250
• Industry data
• May 2013

Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research

• Industries : Pathology
• Countries : World

Togo Prostate Cancer, 70+ Yrs, Male, Dalys

• $ 250
• Industry data
• May 2013

Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research

• Industries : Pathology
• Countries : Togo, World

Micronesia( Federated States Of) Prostate Cancer, 60-69 Yrs, Male, Dalys

• $ 250
• Industry data
• May 2013

Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research

• Industries : Pathology
• Countries : World

Cuba Prostate Cancer, 45-59 Yrs, Male, Dalys

• $ 250
• Industry data
• May 2013

Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research

• Industries : Pathology
• Countries : Cuba, World

Pathology in World

Palau Post-traumatic Stress Disorder, 45-59 Yrs, Male, Dalys

• $ 250
• Industry data
• May 2013

Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research

• Industries : Pathology
• Countries : World

Cote D`ivoire Post-traumatic Stress Disorder, 45-59 Yrs, Male, Dalys

• $ 250
• Industry data
• May 2013

Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research

• Industries : Pathology
• Countries : World

Congo-brazzaville Peptic Ulcer Disease, 45-59 Yrs, Male, Dalys

• $ 250
• Industry data
• May 2013

Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research

• Industries : Pathology
• Countries : World

Mali Post-traumatic Stress Disorder, 45-59 Yrs, Male, Dalys

• $ 250
• Industry data
• May 2013

Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research

• Industries : Pathology
• Countries : Mali, World

Trinidad & Tobago Peptic Ulcer Disease, 45-59 Yrs, Male, Dalys

• $ 250
• Industry data
• May 2013

Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research

• Industries : Pathology
• Countries : World